STOCK TITAN

Elanco Announces Inaugural $600 Million Share Repurchase Authorization

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
buybacks

Elanco Animal Health (ELAN) received board authorization for its first share repurchase program, allowing it to buy back up to $600 million of common stock. The multiyear program does not require Elanco to buy any specific number of shares or spend any specific amount.

Elanco added buybacks to its capital priorities after net leverage fell below 3.0 times ahead of schedule. The company plans to continue paying down debt and investing in growth. Free cash flow reached $362 million as of the end of the third quarter, and Elanco said it is ahead of schedule toward its $1 billion cumulative free cash flow target for 2026 through 2028.

Loading...
Loading translation...
11 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.First multiyear buyback program authorizes repurchases of up to $600 million of Elanco common stock 4.5% of market cap
  • Moderate pointNet leverage fell below 3.0 times ahead of schedule, down approximately three-quarters of a turn in 2026 year to date
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cumulative free cash flow target of $1 billion for 2026 through 2028 is tracking ahead of schedule, Elanco said
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Adjusted earnings per share are expected by Elanco to grow at a low double-digit rate over a multiyear period
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Adjusted EBITDA, a measure of operating earnings, is expected by Elanco to grow at a high single-digit rate over a multiyear period
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Revenue is expected by Elanco to grow at a mid-single-digit rate over a multiyear period
5 minor points
  • Minor pointFree cash flow reached $362 million as of the end of the third quarter
  • Minor point. Forward-looking: it has not happened yet and may not happen.Net leverage of 2.0 to 2.5 times remains within reach, Elanco said
  • Minor point. Forward-looking: it has not happened yet and may not happen.Debt paydown remains a capital allocation priority for Elanco
  • Minor point. Forward-looking: it has not happened yet and may not happen.Growth investment remains a priority, including continued spending on innovation
  • Minor point. Forward-looking: it has not happened yet and may not happen.Cost reductions through Elanco Ascend and lower administrative expenses are a priority to offset inflation

Negative

  • None.

Key Figures

Share repurchase authorization: Up to $600 million Net leverage milestone: Below 3.0x Net leverage ratio path: 2.0 to 2.5 times +3 more
Share repurchase authorization
Up to $600 million
Board-authorized; the program does not require the company to repurchase a specific amount
Net leverage milestone
Below 3.0x
Company says it has reached the targeted sub-3.0x ratio
Net leverage ratio path
2.0 to 2.5 times
Stated path for the net leverage ratio
Cumulative free cash flow target
$1 billion
Target for 2026 to 2028; company says it is tracking ahead of schedule
Free cash flow
$362 million
Reached as of the end of the third quarter
Net leverage ratio reduction
Approximately three-quarters of a turn
2026 year-to-date

Historical Context

1 past event · Latest: Nov 06
1 event
  1. Nov 06

    Q3 earnings

    24h Move
    +8.7%

    Reported 2.9x net leverage, establishing the threshold later cited for capital-allocation flexibility.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

net leverage ratio, free cash flow, adjusted EBITDA, adjusted EPS
4 terms
net leverage ratio financial
"clear path to net leverage ratio of 2.0 to 2.5 times"
The net leverage ratio measures how much debt a company has compared to its available assets or earnings, after accounting for its cash and liquid assets. It helps investors understand how heavily a company relies on borrowed money to finance its operations and growth. A higher ratio indicates greater financial risk, while a lower ratio suggests a more cautious approach to borrowing.
free cash flow financial
"cumulative free cash flow target of $1 billion from 2026 to 2028"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
View in glossary
adjusted EBITDA financial
"high single digit adjusted EBITDA growth"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
adjusted EPS financial
"low double digit adjusted EPS growth"
Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Reflects Strengthening Financial Profile, Strong Cash Flow Generation, Successful Balance Sheet De-Leveraging Below 3x, and Confidence in Continued Momentum

INDIANAPOLIS, Nov. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today its Board of Directors has authorized the repurchase of up to $600 million of the company's common stock. The authorization reflects Elanco's accelerating operational momentum, robust free cash flow generation, strengthened balance sheet and clear path to net leverage ratio of 2.0 to 2.5 times.

Elanco logo

After reaching the targeted sub 3.0x net leverage ratio, the company is updating its capital allocation priorities. Elanco will remain focused on a combination of debt paydown and accretive growth opportunities including continued investment in innovation, while starting a multi-year share repurchase program to drive enhanced, long-term shareholder value.

"Today's authorization of our first-ever share repurchase program reflects Elanco's financial transformation into a consistent, reliable growth company with more than three years of steady quarterly growth," said Jeff Simmons, President and CEO of Elanco. "Our disciplined execution against our Innovation, Portfolio and Productivity (IPP) strategy and expectations of a multi-year runway of mid-single digit revenue growth, high single digit adjusted EBITDA growth and low double digit adjusted EPS growth give us the financial flexibility to accelerate capital return to shareholders, while continuing to fully fund our growth priorities and pipeline to ensure a consistent flow of high-impact innovation."

Over the past several years, Elanco has prioritized debt reduction, successfully reducing its net leverage ratio (NLR) by approximately three-quarters of a turn in 2026 year-to-date alone. Earlier this month, the company reported a major strategic milestone as NLR fell below 3.0x faster than anticipated, unlocking accelerated capital allocation flexibility.

"Our continued strong operational performance and momentum achieving sub-3.0x leverage ahead of schedule gives us confidence to transition to a more balanced capital allocation framework," said Bob VanHimbergen, Executive Vice President and CFO of Elanco. "My priority is driving down costs through Elanco Ascend and general and administrative expenses to compensate for inflation. While there is still more to do, we're pleased with the team's disciplined execution to improve working capital management. We're tracking ahead of schedule toward our cumulative free cash flow target of $1 billion from 2026 to 2028, with free cash flow reaching $362 million as of the end of the third quarter and making continued progress toward our long-term margin goals."

The timing, manner and amount of repurchases will depend on a variety of factors, including market conditions, stock price, alternative capital deployment opportunities, and applicable regulatory requirements. The program does not obligate the company to acquire any specific dollar amount or number of shares and may be modified, suspended, or discontinued at any time without prior notice.

About Elanco
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning our expectations regarding debt levels and capital allocation, expectations regarding our industry, operations, performance and financial condition and expectations regarding growth strategies, product development efforts and future expenses. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, and additional factors that could cause actual results to differ materially from forward-looking statements described in the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Dekker (317) 989-7011 colleen.dekker@elancoah.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-announces-inaugural-600-million-share-repurchase-authorization-302944490.html

SOURCE Elanco Animal Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much stock can Elanco buy back under its first share repurchase program?

Elanco can repurchase up to $600 million of its common stock under the multiyear authorization. It is not obligated to buy any specific number of shares or spend any specific amount.

What will determine when Elanco buys back shares and how much it buys?

The timing, method and amount of Elanco's buybacks depend on market conditions, the stock price, other uses for capital and applicable regulatory requirements. Elanco can modify, suspend or end the program at any time without prior notice.

Keep reading